
UB341
TargetsTL1A; IL-23p19
IndicationsInflammatory bowel disease; Psoriasis
ClinicalCN - Pre-IND
TherapeuticsDermatology
ModalitiesAntibody
Asset Materials

How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →